Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma - Validation of utility as a clinical marker
Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma - Validation of utility as a clinical marker
复制标题
DOI：
10.1097/00000658-199803000-00012
复制
发表时间：
1998-03-01
影响因子：
9
通讯作者：
Carty, SE
中科院分区：
文献类型：
--
作者：
Goydos, JS;Brumfield, AM;Carty, SE
目的探讨肝恶性肿瘤患者血清白细胞介素6（IL-6）水平是否升高或与放射学肿瘤负荷相关。IL-6是胆管上皮细胞的生长因子。MethodsUsing生物活性和酶联免疫吸附试验，血清IL-6水平测定在35名健康成人和60例患者提出的胆管癌（CC）（15例），肝细胞癌（HCC）（14），转移性结直肠癌（MCRC）（26），良性胆道疾病（BED）（5）的最终管理。排除了已知具有升高IL-6血清水平的临床状况的患者。根据同时进行的计算机断层扫描计算肿瘤负荷。在3例CC患者中，在切除后2周测量IL-6水平。IL-6的分泌检测在3人CC细胞株。结果一个升高的水平检测到生物活性IL-6在每个CC患者和13 14例HCC患者，14 26例MCRC患者，2 5例BED患者，3 35例健康成人。CC中生物活性IL-8的中值和平均水平高于其他肿瘤（p < 0.026），并且所有肿瘤组均不同于健康成人（p小于或等于0.026）。IL-6水平在原发性肝肿瘤中比在继发性肝肿瘤中更常升高（p = 0.02），区分CC或MCRC与BED患者（分别为p = 0.014和0.031），与CC中的肿瘤负荷相关（p < 0.001），并且在CC切除后急剧下降。CC细胞系SG 231分泌具有生物活性的IL-6。结论在选择的患者中，高水平的IL-8标志着CC患者，并与手术前后的肿瘤负荷相关。IL-6水平在其他肝肿瘤患者中升高，并可将肝恶性肿瘤患者与良性疾病患者区分开来。
ObjectiveTo determine if the serum level of interleukin-6 (IL-6) was elevated in patients with hepatic malignancies or correlated with radiologic tumor burden.Summary Background DataHigh serum levels of IL-B signify an adverse prognosis in many patients with cancer. IL-6 is a growth factor for bile duct epithelium.MethodsUsing bioactive and enzyme-linked immunosorbent assays, serum level of IL-6 was measured in 35 healthy adults and in 60 patients presenting for definitive management of cholangiocarcinoma (CC) (15 patients), hepatocellular carcinoma (HCC) (14), metastatic colorectal cancer (MCRC) (26), and benign biliary disease (BED) (5). Patients with clinical conditions known to raise the serum level of IL-6 were excluded. Tumor burden was calculated from concurrent computed tomography scans. IL-6 levels were measured 2 weeks after resection in 3 CC patients. Secretion of IL-6 was examined in 3 human CC cell lines.ResultsAn elevated level of bioactive IL-6 was detected in every patient with CC and in 13 of 14 patients with HCC, 14 of 26 patients with MCRC, 2 of 5 patients with BED, and 3 of 35 healthy adults. Median and mean levels of bioactive IL-8 were higher in CC than in other neoplasms (p < 0.026) and for all tumor groups differed from healthy adults (p less than or equal to 0.026). IL-6 level was elevated more often in primary than in secondary liver neoplasms (p = 0.02), distinguished patients with CC or MCRC from BED (p = 0.014 and 0.031, respectively), correlated with tumor burden in CC (p < 0.001), and dropped sharply after CC resection. CC line SG231 secreted bioactive IL-6.ConclusionsIn selected patients, a high serum level of IL-8 marks patients with CC and correlates with tumor burden both before and after resection. IL-6 levels are elevated in patients with other liver neoplasms and may distinguish patients with hepatic malignancies from those with benign disease.